Roth Capital assumed coverage on shares of Merus (NASDAQ:MRUS) in a research report released on Friday, June 28th, FirstToMarketsRatingsTable reports. The firm issued a buy rating and a $20.00 price objective on the biotechnology company’s stock.
A number of other equities research analysts have also recently weighed in on MRUS. Citigroup cut Biogen from a buy rating to a neutral rating and dropped their price target for the company from $470.00 to $230.00 in a research note on Thursday, March 21st. Zacks Investment Research upgraded Jack Henry & Associates from a sell rating to a hold rating in a research note on Wednesday, March 27th. Guggenheim cut Anadarko Petroleum from a buy rating to a hold rating and set a $69.00 price objective on the stock. in a research report on Friday, April 12th. Royal Bank of Canada set a €5.70 ($6.63) price objective on Banco Santander and gave the stock a buy rating in a research report on Wednesday, April 3rd. Finally, Wedbush increased their price objective on Urban Outfitters from $30.00 to $35.00 and gave the stock a hold rating in a research report on Friday, April 5th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company. Merus currently has a consensus rating of Buy and an average target price of $22.57.
Shares of Merus stock traded down $0.01 on Friday, reaching $15.00. 5,345 shares of the company were exchanged, compared to its average volume of 30,681. Merus has a one year low of $11.00 and a one year high of $24.37. The firm has a market cap of $341.49 million, a P/E ratio of -8.15 and a beta of 0.22. The firm’s 50-day moving average is $14.21.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC grew its holdings in shares of Merus by 10.3% during the 4th quarter. Squarepoint Ops LLC now owns 11,800 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 1,100 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Merus by 18.8% during the 4th quarter. Geode Capital Management LLC now owns 14,987 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 2,373 shares in the last quarter. Morgan Stanley boosted its stake in Merus by 74.3% in the third quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock valued at $1,415,000 after buying an additional 30,538 shares in the last quarter. Finally, Granite Investment Partners LLC acquired a new stake in Merus in the first quarter valued at about $468,000. 52.13% of the stock is currently owned by institutional investors.
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Recommended Story: How to use beta for portfolio diversification
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.